These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
368 related articles for article (PubMed ID: 7682911)
41. Adverse effects of antimalarials. An update. Luzzi GA; Peto TE Drug Saf; 1993 Apr; 8(4):295-311. PubMed ID: 8481216 [TBL] [Abstract][Full Text] [Related]
42. Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. Nosten F; Karbwang J; White NJ; Honeymoon ; Na Bangchang K; Bunnag D; Harinasuta T Br J Clin Pharmacol; 1990 Jul; 30(1):79-85. PubMed ID: 2390434 [TBL] [Abstract][Full Text] [Related]
46. Complex Membrane Channel Blockade: A Unifying Hypothesis for the Prodromal and Acute Neuropsychiatric Sequelae Resulting from Exposure to the Antimalarial Drug Mefloquine. Quinn JC J Parasitol Res; 2015; 2015():368064. PubMed ID: 26576290 [TBL] [Abstract][Full Text] [Related]
47. Idiosyncratic quinoline central nervous system toxicity: Historical insights into the chronic neurological sequelae of mefloquine. Nevin RL Int J Parasitol Drugs Drug Resist; 2014 Aug; 4(2):118-25. PubMed ID: 25057461 [TBL] [Abstract][Full Text] [Related]
48. Trioxolane-Mediated Delivery of Mefloquine Limits Brain Exposure in a Mouse Model of Malaria. Lauterwasser EM; Fontaine SD; Li H; Gut J; Katneni K; Charman SA; Rosenthal PJ; Bogyo M; Renslo AR ACS Med Chem Lett; 2015 Nov; 6(11):1145-9. PubMed ID: 26617969 [TBL] [Abstract][Full Text] [Related]
49. A serious nightmare: psychiatric and neurologic adverse reactions to mefloquine are serious adverse reactions. Nevin RL Pharmacol Res Perspect; 2017 Aug; 5(4):. PubMed ID: 28805982 [TBL] [Abstract][Full Text] [Related]
50. Development of Resistance Against Mefloquine Prophylaxis in Peace-Keeping Forces in the Central African Republic. Malik JA; Nadeem A; Khalid Z; Nadeem Y; Zaffar S; Siddiqui AH Cureus; 2020 Jun; 12(6):e8886. PubMed ID: 32742853 [TBL] [Abstract][Full Text] [Related]
52. Antimalarial drugs and the prevalence of mental and neurological manifestations: A systematic review and meta-analysis. Bitta MA; Kariuki SM; Mwita C; Gwer S; Mwai L; Newton CRJC Wellcome Open Res; 2017; 2():13. PubMed ID: 28630942 [No Abstract] [Full Text] [Related]
53. Blood to plasma ratio of mefloquine: interpretation and pharmacokinetic implications. Tajerzadeh H; Cutler DJ Biopharm Drug Dispos; 1993 Jan; 14(1):87-91. PubMed ID: 8427948 [TBL] [Abstract][Full Text] [Related]
55. A Pharmacokinetic Study of Antimalarial 3,5-Diaryl-2-aminopyridine Derivatives. Dambuza N; Smith P; Evans A; Taylor D; Chibale K; Wiesner L Malar Res Treat; 2015; 2015():405962. PubMed ID: 25893131 [TBL] [Abstract][Full Text] [Related]
56. How can we do pharmacokinetic studies in the tropics? Simpson JA; Aarons L; White NJ Trans R Soc Trop Med Hyg; 2001; 95(4):347-51. PubMed ID: 11579871 [TBL] [Abstract][Full Text] [Related]
57. Differential Stabilities of Mefloquine-Bound Human and Kumar A; Ghosh DK; Ranjan A ACS Omega; 2021 Jan; 6(3):1883-1893. PubMed ID: 33521428 [TBL] [Abstract][Full Text] [Related]
58. The Intersection Between Malaria Treatment and Chemoprophylaxis and Their Potential Adverse Dermatologic Manifestations: A Narrative Review. Farkouh CS; Anthony MR; Amatul F; Abdi P; Ali Khan Q Cureus; 2023 Mar; 15(3):e36066. PubMed ID: 37065311 [TBL] [Abstract][Full Text] [Related]
59. Neuropsychiatric Aspects of Parasitic Infections-A Review. Goyal G; Kaur U; Sharma M; Sehgal R Neurol India; 2023; 71(2):228-232. PubMed ID: 37148042 [TBL] [Abstract][Full Text] [Related]